Patent · US Active

Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies

US12419954B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignees

City of Hope · US
The Board of Trustees of the Leland Stanford Junior University · US

Inventors

Christine E. Brown · Duarte, US
Lawrence Stern · Duarte, US
Xin Yang · 浮桥镇, CN
K. Christopher Garcia · Menlo Park, US
Ignacio Moraga Gonzalez · Palo Alto, US

Key dates

Filing date	Jan 19, 2021
Grant date	Sep 23, 2025
Priority date	—
Expiry date	Mar 24, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2239/47
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Chimeric antigen receptor molecules that include a variant IL-13. The variant IL-13 are more selective for IL13Rα2 than IL13Rα1 by virtue of weaker binding to IL13Rα1. The chimeric antigen receptors can be used to treat IL13Rα2 expressing cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.